AXIM® Biotechnologies, Inc., a world leader in cannabinoid research and product development, announced that the United States Patent and Trademark Office (USPTO) has issued the company a new Notice of Allowance for a patent (Application No. 16/122,079) on a suppository composition comprising cannabinoids.
The Notice of Allowance is a continuation of AXIM’s patent (US 10,092,538 B2) granted to the Company in October 2018.
Cannabinoids covered under the patent include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabinol (THC), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV), other cannabinoids, or a combination of all or some of these.
AXIM® Biotechnologies suppository composition is formulated for easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with nausea, vomiting, other conditions related to swallowing or conditions wherein suppository administration is required.
Suppositories made under the patent will aim to reduce symptoms related to pain, nausea, postoperative ileus and/or inflammatory bowel disease (IBD).
What is inflammatory bowel disease (IBD)?
Inflammatory bowel disease (IBD) is an umbrella term used to describe medical disorders that involve chronic inflammation of your digestive tract.
What are suppositories?
A suppository is a small, round or cone-shaped object that you put in your body, often into your rectum. Once inside it melts or dissolves and releases its medication.
Suppositories are not the most attractive product you’ll ever use, but they can make it easier to take medication for those who are unable to swallow large pills.
Suppositories are also for those whose stomach or intestines wouldn’t absorb medication well.
CBD suppositories are a great way to medicate as they have a high bioavailability and allows the cannabinoids to bypass the stomach and the liver.